TABLE 3.
Explanatory variable | Peak IL-2+ SFC |
Peak IFN-γ+ SFC |
Peak IFN-γ+ IL-2+ SFC |
|||
---|---|---|---|---|---|---|
RCE | P | RCE | P | RCE | P | |
Age | 1.75 | 0.14 | −0.69 | 0.67 | 1.20 | 0.15 |
Baseline responses | 1.18 | <0.0001 | 1.64 | <0.0001 | 1.21 | <0.0001 |
VZV-specific CD4+ CD39+ | −76.5 | 0.02 | −71.7 | 0.09 | −51.2 | 0.03 |
VZV-specific CD8+ CD39+ | 18.3 | 0.32 | 4.22 | 0.86 | 23.9 | 0.07 |
VZV-specific CD4+ FOXP3+ | 107.4 | 0.04 | 141.6 | 0.04 | 86.5 | 0.021 |
VZV-specific CD8+ FOXP3+ | 1.18 | 0.96 | 48.2 | 0.17 | 10.8 | 0.57 |
VZV-specific CD4+ IL-10+ | −23.5 | 0.68 | −122 | 0.1 | 9.6 | 0.81 |
VZV-specific CD8+ IL-10+ | 30.3 | 0.41 | 73.8 | 0.12 | 0.46 | 0.99 |
VZV-specific CD4+ TGF-β+ | −17.9 | 0.46 | 9.9 | 0.75 | −6.0 | 0.73 |
VZV-specific CD8+ TGF-β+ | 1.3 | 0.92 | −2.1 | 0.91 | −1.8 | 0.85 |
Boldface type indicates statistically significant effects defined by a P value of <0.02 to adjust for multiple comparisons. Abbreviations: VZV, varicella-zoster virus; Th1, T helper 1; CTL, cytotoxic T lymphocytes; RCE, regression coefficient estimate (indicates the magnitude of the effect of the explanatory variable on the outcome measure); SFC, spot-forming cells/106 PBMC; baseline responses, prevaccination responses in the same category as the outcome measure (e.g., prevaccination IFN-γ SFC as an explanatory variable for peak IFN-γ SFC or prevaccination IL-2 SFC as an explanatory variable for peak IL-2 SFC, etc.).